Walleye Capital
JANX icon

Walleye Capital’s Janux Therapeutics JANX Stock Holding History

Walleye Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Sell
29,900
-13,700
-31% -$198K ﹤0.01% 2831
2026
Q1 		$606K Buy
43,600
+39,600
+990% +$543K ﹤0.01% 2505
2025
Q4 		$55.2K Buy
+4,000
New +$94.1K ﹤0.01% 4051
2024
Q3 		– Sell
-2,900
Closed -$121K – 5576
2024
Q2 		$121K Buy
+2,900
New +$136K ﹤0.01% 4623

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Walleye Capital's JANX Position: Q2 2026 in Review

Walleye Capital reduced its Janux Therapeutics (JANX) stake by 52% in Q2 2026, selling an estimated $989K and leaving 62,338 shares worth $958K. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

Walleye Capital first reported a position in JANX in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.46M in Q4 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Walleye Capital held 62,338 shares of Janux Therapeutics worth $958K as of Q2 2026.
  • Walleye Capital sold 68,280 Janux Therapeutics shares in Q2 2026, an estimated $989K.
  • Janux Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2160 holding.
  • Walleye Capital first reported a position in Janux Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Walleye Capital's Janux Therapeutics position peaked at $4.46M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.